<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02640534</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 08/14 - IMPROVE</org_study_id>
    <nct_id>NCT02640534</nct_id>
  </id_info>
  <brief_title>Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone</brief_title>
  <official_title>Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test if the combination of enzalutamide and metformin in&#xD;
      patients with castration resistant prostate cancer CRPC progressing on androgen deprivation&#xD;
      therapy ADT is more effective compared to enzalutamide alone. The half of the patients will&#xD;
      receive the experimental treatment combination, enzalutamide and metformin, while the other&#xD;
      half will receive enzalutamide alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One in seven men will be diagnosed with cancer of the prostate during his lifetime .&#xD;
      Accordingly, prostate cancer (PC) is the most common cancer amongst men in the western world&#xD;
      and worldwide. PC ranks second in cancer incidence and sixth in cancer mortality in men. The&#xD;
      current standard of care for patients with metastatic castration resistant prostate cancer&#xD;
      (mCRPC) and disease progression is either treatment with abiraterone acetate and prednisone&#xD;
      in asymptomatic or mildly symptomatic patients without visceral metastases, or treatment with&#xD;
      docetaxel in more symptomatic patients and in the presence of visceral metastases.&#xD;
&#xD;
      Rothemundt et al. previously demonstrated favorable effects of metformin in a phase II trial:&#xD;
      it yields objective Prostate specific antigen PSA responses and may induce disease&#xD;
      stabilization and improve metabolic endpoints in patients with CRPC. Therefore addition of&#xD;
      metformin to enzalutamide might have positive impact on tumor progression, on body&#xD;
      composition, and insulin sensitivity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2016</start_date>
  <completion_date type="Anticipated">March 2028</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease control (DC)</measure>
    <time_frame>at 15 months</time_frame>
    <description>The primary endpoint of the trial is disease control (DC) at 15 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response (OR)</measure>
    <time_frame>at 15 months</time_frame>
    <description>Overall response (OR) according to modified RECIST and PCWG2 recommendations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival (EFS)</measure>
    <time_frame>at 15 months</time_frame>
    <description>EFS is defined as the time from randomization until progression or death due to any reason.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>at 15 months</time_frame>
    <description>AEs will be assessed according to NCI CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 15 months</time_frame>
    <description>OS will be calculated from randomization until death due any reason.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">169</enrollment>
  <condition>Cancer of the Prostate</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Enzalutamide 160 mg od + metformin 850 mg bid until disease progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enzalutamide 160 mg od until disease progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Enzalutamide 160 mg od until disease progression</description>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg bid until disease progression</description>
    <arm_group_label>Enzalutamide + Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations before registration and&#xD;
             prior to any trial-related investigations&#xD;
&#xD;
          -  Histologically or cytological confirmed adenocarcinoma of the prostate without small&#xD;
             cell carcinoma or small cell components&#xD;
&#xD;
          -  Asymptomatic or minimally symptomatic patients in relation to disease&#xD;
&#xD;
          -  Metastatic adenocarcinoma of the prostate documented by imaging (CT/MRI and/or bone&#xD;
             scan)&#xD;
&#xD;
          -  Ongoing androgen deprivation therapy with Gonadotropin-releasing hormone GnRH&#xD;
             analogues or bilateral orchiectomy (i.e. surgical or medical castration)&#xD;
&#xD;
          -  Total testosterone levels ≤ 1.7 nmol/L (corresponding to ≤ 50 ng/dL)&#xD;
&#xD;
          -  Tumor progression at the time of registration, defined as per protocol.&#xD;
&#xD;
          -  Completed baseline QoL and pain questionnaires&#xD;
&#xD;
          -  Male patients ≥ 18 years&#xD;
&#xD;
          -  WHO performance status 0-2&#xD;
&#xD;
          -  Adequate hematologic values: hemoglobin ≥ 90 g/L, neutrophils ≥ 1.0 x 109/L, platelets&#xD;
             ≥ 75 x 109/L&#xD;
&#xD;
          -  Adequate hepatic function: ALT and AST ≤ 2.5 x ULN, bilirubin ≤ 1.5 x ULN (exception&#xD;
             if Gilbert's syndrome ≤ 2.5 x ULN)&#xD;
&#xD;
          -  Adequate renal function: calculated creatinine clearance ≥ 50 mL/min, according to the&#xD;
             formula of Cockcroft-Gault&#xD;
&#xD;
          -  Patient is able to swallow the trial drugs and comply with trial requirements&#xD;
&#xD;
          -  Patient agrees not to father a child during participation in the trial and during 3&#xD;
             months thereafter&#xD;
&#xD;
          -  Patient agrees to participate to the mandatory translational research part of the&#xD;
             trial with exception of Pyruvate dehydrogenase sub-study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected Central nervous system CNS metastases or active leptomeningeal&#xD;
             disease&#xD;
&#xD;
          -  Previous malignancy within 2 years prior to registration, with the exception of&#xD;
             localized non-melanoma skin cancer and Ta and Tis bladder cancer&#xD;
&#xD;
          -  Prior treatment for prostate cancer with&#xD;
&#xD;
               -  novel endocrine agents (including abiraterone acetate, enzalutamide, TAK-700,&#xD;
                  TAK-683, TAK-448, VT464, darolutamide, apalutamide),&#xD;
&#xD;
               -  radioisotopes,&#xD;
&#xD;
               -  TKI and other small molecules,&#xD;
&#xD;
               -  immunotherapy,&#xD;
&#xD;
               -  chemotherapy (with the exception of docetaxel chemotherapy in hormone sensitive&#xD;
                  prostate cancer)&#xD;
&#xD;
          -  Treatment with experimental drugs or treatment within a clinical trial within 30 days&#xD;
             prior to registration (except the clinical trial SAKK 96/12, PEACE-4 and/or the&#xD;
             biobank project SAKK 63/12)&#xD;
&#xD;
          -  Clinically significant cardiovascular disease including:&#xD;
&#xD;
               -  Myocardial infarction within 6 months prior to registration,&#xD;
&#xD;
               -  Uncontrolled angina within 3 months prior to registration,&#xD;
&#xD;
               -  Congestive heart failure NYHA class III or IV,&#xD;
&#xD;
               -  QTc interval &gt; 480 ms,&#xD;
&#xD;
               -  History of clinically significant ventricular arrhythmias (e.g. ventricular&#xD;
                  tachycardia, ventricular fibrillation, torsades de pointes),&#xD;
&#xD;
               -  History of Mobitz II second or third degree heart block without a permanent&#xD;
                  pacemaker in place,&#xD;
&#xD;
               -  Uncontrolled hypertension as indicated by systolic blood pressure &gt; 170 mmHg OR&#xD;
                  diastolic blood pressure &gt; 105 mmHg&#xD;
&#xD;
          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the&#xD;
             investigator, would make the patient inappropriate for enrollment (e.g. uncontrolled&#xD;
             or acute severe infection, advanced chronic obstructive pulmonary disease, heart&#xD;
             failure)&#xD;
&#xD;
          -  Known history of HIV, hepatitis B, hepatitis C&#xD;
&#xD;
          -  Major surgery within 4 weeks prior to registration&#xD;
&#xD;
          -  Gastrointestinal disorder affecting absorption (e.g., gastrectomy, active peptic ulcer&#xD;
             disease within 3 months prior to registration)&#xD;
&#xD;
          -  Treatment with metformin within the last 6 months prior to registration&#xD;
&#xD;
          -  Patients on pharmacotherapy for diabetes mellitus&#xD;
&#xD;
          -  History of diabetic ketoacidosis, diabetic coma and pre-coma&#xD;
&#xD;
          -  Known history of seizures or any conditions that may predispose to seizure. History of&#xD;
             loss of consciousness or transient ischemic attack within 12 months prior to&#xD;
             registration&#xD;
&#xD;
          -  Concurrent anticoagulation with rivaroxaban or warfarin&#xD;
&#xD;
          -  Known hypersensitivity to the IMPs or hypersensitivity to any of their components&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the IMPs according to the&#xD;
             Swissmedic approved product information&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the trial protocol and follow-up.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Rothermundt, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico della Svizzera Italiana (IOSI)</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubuenden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau AG</name>
      <address>
        <city>Frauenfeld</city>
        <zip>CH-8500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires de Genève</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Luzerner Kantonsspital</name>
      <address>
        <city>Luzern 16</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais</name>
      <address>
        <city>Martigny</city>
        <zip>1920</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn</name>
      <address>
        <city>Solothurn</city>
        <zip>CH-4500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stadtspital Triemli</name>
      <address>
        <city>Zürich</city>
        <zip>8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UniversitätsSpital Zürich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>December 22, 2015</study_first_submitted>
  <study_first_submitted_qc>December 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>Cancer of the prostate</keyword>
  <keyword>Metformin</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>Xtandi</keyword>
  <keyword>castration resistant prostate cancer</keyword>
  <keyword>phase II</keyword>
  <keyword>Androgen deprivation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

